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INTRODUCTION 
Usually conventional dosage form produce wide ranging fluctuation in drug 
concentration in the blood stream and tissues with consequent undesirable toxicity and 
poor efficiency. This factor such as repetitive dosing and unpredictable absorption led 
to the concept of controlled drug delivery systems. The goal in designing sustained or 
controlled delivery systems is to reduce the frequency of the dosing or to increase 
effectiveness of the drug by localization at the site of action, reducing the dose required 
or providing uniform drug delivery. The primary objective of sustained release drug 
delivery is to ensure safety and to improve efficacy of drugs as well as patient 
compliance
1
. Bi-layer tablet is suitable for sequential release of two drugs in 
combination, separate two incompatible substances and also for sustained release tablet 
in which one layer is immediate release as initial dose and second layer is maintenance 
dose
2
. In the case of bi-layered tablets drug release can be rendered almost 
unidirectional if the drug can be incorporated in the upper non-adhesive layer its 
delivery occurs into the whole oral cavity. 
BI-LAYER TABLETS
3 
Bilayer tablet is a unit compressed tablet dosage form intended for all oral 
administration. It comprises of two layers in which one layer is formulated as a 
conventional or immediate release part and another layer as modified release part or 
both of the former or later of the same or different drugs. 
The goal in designing delayed release sustained or controlled delivery system is to: 
Reduce the frequency of dosing or to increase effectiveness of the drug by localization 
at the site of action, reducing the dose required, or providing uniform drug delivery. 
 It would be a single dose for the duration of treatment whether it is for days or 
weeks, as with infection, or for the life time of the patient, as in hypertension or 
diabetes. 
 It should deliver the active entity directly to the site of action, minimizing or 
eliminating side effects.  
 This may necessitate delivery to specific receptors or to localization to cells or 
to specific areas of the body
4
  
 The safety margin of high potency drug can be increase and the incidence of 
both local and systemic adverse side effects can be reduced in sensitive patient
5
  
Advantages 
 Decreased in dosing frequency  
 Reduced peak to trough ratio of drug in systemic circulation.  
 Reduced rate of rise of drug concentration in blood.  
 Sustained & Consistent blood level with in the therapeutic window.  
 Enhanced bioavailability  
 Customized delivery profiles  
 Reduced side effects  
 Improved patient compliance  
Quality and GMP-requirements: 
 To produce a quality bi-layer tablet, in a validated and GMP-way, it is important 
that the selected press is capable of
6
 
 Preventing capping and separation of the two individual layers that constitute 
the bi-layer tablet  
 Providing sufficient tablet hardness 
 Preventing cross-contamination between the two layers 
 Producing a clear visual separation between the two layers  
 High yield  
 Accurate and individual weight control of the two layers is not so easily 
accomplished as this article aims to demonstrate.  
Manufacturing aspect: 
The manufacture of bi-layer tablets, produced by the sequential compaction of loose 
powder layers has recently become of increased interest within the pharmaceutical 
industry due to the tailored release profiles of active ingredients that may be obtained
7, 8
 
An observed disadvantage of the formulation however, is the predilection of the 
assemblies to fail at the interfacial boundary zone between the two adjacent layers. 
 
Various Techniques: 
OROS® push pull technology: 
This system consist of mainly two or three layer among which the one or more layer are 
essential of the drug and other layer are consist of push layer (Fig.1). The drug layer 
mainly consists of drug along with two or more different agents. So this drug layer 
comprises of drug which is in poorly soluble form. There is further addition of 
suspending agent and osmotic agent. A semi permeable membrane surrounds the tablet 
core. 
 
Fig1: Bilayer and trilayer OROS Push pull technology. 
L-OROS tm technology: 
This system used for the solubility issue Alza developed the L-OROS system where a 
lipid soft gel Product containing drug in a dissolved state is initially manufactured and 
then coated with a barrier membrane, than osmotic push layer and than a semi 
permeable membrane, drilled with an exit orifice (Fig.2). 
 
Fig 2: L–OROS tm technology. 
 
EN SO TROL technology: 
Solubility enhancement of an order of magnitude or to create optimized dosage form 
Shire laboratory use an integrated approach to drug delivery focusing on identification 
and incorporation of the identified enhancer into controlled release technologies
1
. 
DUROS technology: 
The system consists from an outer cylindrical titanium alloy reservoir (Fig. 3).This 
reservoir has high impact strength and protects the drug molecules from enzymes. The 
DUROS technology is the miniature drug dispensing system that opposes like a 
miniature syringe and reglious minute quantity of concentrated form in continues and 
consistent from over months or Year. 
 
Fig 3: DUROS Technology 
Elan drug technologies’ Dual release drug delivery system: 
DUREDAS™ Technology is a bilayer tablet which can provide immediate or sustained 
release of two drugs or different release rates of the same drug in one dosage form. The 
tab letting process can provide an immediate release granulate and a modified-release 
hydrophilic matrix complex as separate layers within the one tablet. The modified-
release properties of the dosage form are provided by a combination of hydrophilic 
polymers. 
Benefits offered by the DUREDAS™ technology include: 
 Bilayer tabletting technology. 
 Tailored release rate of two drug components. 
 Capability of two different CR formulations combined. 
 Capability for immediate release and modified release components in one 
tablet. 
 Unit dose, tablet presentation. 
The DUREDAS™ system can easily be manipulated to allow incorporation of two 
controlled release formulations in the bi-layer. Two different release rates can be 
achieved from each side. In this way greater prolongation of sustained release can be 
achieved. Typically an immediate release granulate is first compressed followed by the 
addition of a controlled release element which is compressed onto the initial tablet. This 
gives the characteristic bilayer effect to the final dosage form. A further extension of 
the DUREDAS™ technology is the production of controlled release combination 
dosage forms whereby two different drugs are incorporated into the different layers and 
drug release of each is controlled to maximize the therapeutic effect of the combination. 
Again both immediate release and controlled release combinations of the two drugs are 
possible. A number of combination products utilizing this technology approach have 
been evaluated. The DUREDAS™ technology was initially employed in the 
development of a number of OTC controlled release analgesics. In this case a rapid 
release of analgesic is necessary for a fast onset of therapeutic effect. Hence one layer 
of the tablets is formulated as immediate releases granulate. By contrast, the second 
layer of the tablet, through use of hydrophilic polymers, releases drug in a controlled 
manner. The controlled release is due to a combination of diffusion and erosion through 
the hydrophilic polymer matrix.  
BI-LAYER TABLET PRESS 
The XM 12 Bi-Layer Tablet Press features a retractable second layer feeder that permits 
automated first layer sampling at production speeds. The first layer sampling capability 
also offers a hardening feature, which the main compression station will automatically 
compress, the first layer tablet for in-process measurement. The two feeders are zero 
clearance and are configured with an integrated dust extraction manifold which cleans 
the die table and completely eliminates any potential for cross contamination. 
WipCon® solution available for potent for layer Tablet Press is a small-scale press 
which is ideal for product development scale-up, clinical trials and midrange 
production. The bi-layer execution, single-layer conversion kit and exchangeable turret 
offer unprecedented flexibility. The XM 12 Bi-Layer Tablet Press offers a new standard 
in GMP with extreme accessibility to the compression zone and combinations of quick 
disconnects and smooth surfaces that permit fast cleaning and changeover. 
The machine concept: 
Advantages: 
1. Flexible Concept 
 Bi-Layer execution with optional single-layer conversion kit 
 Exchangeable turret 
 Turret sizes for product development, scale-up, and mid-range 
production 
 Full production capability in a scale-up machine 
 Self-contained, fully portable design 
2. Fast and Easy Changeover 
 Internal turret lift device for extreme simplicity in turret removal and 
installation 
 Clean compression zone with quick-disconnect design 
3. Design Advantages 
 Small-scale bi-layer capability 
 Robust caster base permits full portability 
 Large touch screen flush mounted 
 Unique structural design eliminates vibration and noise 
 Zero clearance feeder for maximum yield and optimal layer separation 
 Retractable second layer feeder for automatic first layer sampling 
4. Full instrumentation 
 Tamping force 
 Pre/Main compression force 
 Ejection force 
5. Touch Screen Control 
 Press force control and single tablet rejection capability 
 Comprehensive data collection and analysis capability 
 Real time display and batch data documentation 
6. Containment Solution 
 WipCon® solution available for potent products. 
 Applications of bi-layer for small scale: 
The KORSCH XM 12 Bi-Layer Tablet Press is a small scale press which is ideal for 
product development, scale-up, Clinical trials, and midrange production. The bi-layer 
execution, single-layer conversion kit, and exchangeable turret Offer unprecedented 
flexibility. The XM 12 Bilayer tablet Press offers a new standard in GMP with extreme 
accessibility to the compression zone and combination of quick disconnects and 
smooths surfaces that permit fast cleaning and changeover. The machine features a 5 
kN tamping station, 40 kN precompression station, 80 kN main compression station, 
and a unique structural design that eliminates vibration to the head piece and base 
frame. The result is an extreme reduction in the operating noise level. The XM 12 
Bilayer tablet Press features a retractable second speeds. The first layer sampling 
capability also offers a hardening feature, in which the main compression station will 
automatically compress the first layer tablet for in-process measurement. The two 
feeders are zero clearance and are configured with an integrated dust extraction 
manifold, which cleans the die table and completely eliminates any potential for cross-
contamination.  
Properties: 
 Free format graphic and statistical analysis to allow the export of many data 
formats. 
 Reports can be automatically generated in a variety of data formats with and 
without an electronic signature. 
 Charts can be dimensioned, comments added, formatted and exported before 
being processed in the MS Office world. 
 Finger print recording during production. Overlay Technology allows safe and 
quick recognition of subsequent waveforms. 
 Correlation Analysis to establish a “Knowledge Database” that serves to easily 
compare the properties of known and unknown ingredients. The database 
enables the user to correlate measuring values from the tableting process and 
derived and externally recorded quantities (e.g. tablet hardness, density, etc.). 
 Compaction Analysis allows evaluations e.g. Heckel plot, energy, work of 
compression, contact time, compressibility. 
 “Built-in” PAT function, i.e. the database is automatically filled with process 
data thereby helping to define and complete PAT requirement for Knowledge 
Space and Design Space. 
XM 12 WipCon® development & analysis: 
 Minimum space requirements, portable design 
 Best cleaning / decontamination results for product specific demands 
 Optimized glove port configuration 
 All types of make/break connections possible 
 High containment range for lab scale and medium size batches OEB 5 (1 μg/m³ 
> OEL >0.1 μg/m³) with RTP transfer system 
 Medium containment range for small production batches OEB 4 (10 μg/m³ > 
OEL > 1 μg/m³) with split valve connections 
 Connection to Wip tablet deduster on same containment level OEB 4 (10 μg/m³ 
> OEL >1 μg/m³) 
 Negative pressure control and safe-change filter box attached or separate, 
depending on space availability. 
Table 1: some examples for combination of drugs used as bilayer tablets 
Combination of drugs Reason 
Metformin HCl + 
Pioglitazone 
Reduce frequency of administration and improve 
patient compliance
11
. 
Diltiazem HCl + Lovastatin 
Improve patient compliance and better disease 
management
12
. 
Metoprolol succinate + 
Amlodipine besylate 
Lower doses of drug to reduce patient blood 
pressure; minimize dose dependent side effects and 
adverse reaction
13
. 
Solbutamol + Theophylline 
Enhance patient compliance and prolonged 
bronchodilation
14
. 
Paracetamol + Diclofenac 
sodium 
Reduce dose frequency and decrease incidence of GI 
side effects
15
. 
Tramadol + Acetaminophen 
Prolonged release up to 12 hrs and improve patient 
compliance
16
. 
 
 
LITERATURE REVIEW 
REVIEW OF BILAYER TABLET 
Jagadeesh Singh SD et at., (2011)
9
 reported that over the past 30 years as the expense 
and complications involved in marketing new drug entities have increased, with 
concomitant recognition of the therapeutic advantages of controlled drug delivery, 
greater attention has been focused on development of sustained or controlled release 
drug delivery systems. Bilayer tablet is new era for the successful development of 
controlled release formulation along with various features to provide a way of 
successful drug delivery system 
Patel Mehul et al., (2010)
10
 reported that several pharmaceutical companies are 
currently developing bi-layer tablets, for a variety of reason: patent extension, 
therapeutic, marketing tool name a few. To reduce capital investment, quite often 
existing but modified tablets presses are used to develop and produced such tablet.   
Ramesh et al., (2010)
11
 established metformin HCL SR 1000 mg and pioglitazone 
HCL 15 mg in the form of bi-layered sustained release matrix tablets and prepared 
using sodium carboxymethylcellulose and hydroxypropyl methylcellulose as bio-
adhesive polymer and cross carmellose sodium to act as an impermeable backing layer. 
The formulation gave an immediate release effect followed by sustained release for 8 
hrs. The stability studies of formulated product also comply with ICH guidelines. 
 
Kulkarni et al., (2008)
12
 developed bilayer floating tablet of ditiazem HCl and 
lovastatin. The tablet cosists of SSG as superdisintegrant for lovastatin in the IR layer 
and HPMC k4M and xanyhan gum as release retarding agents for diltiazem HCl in the 
controlled release layer. Sodium bicarbonate was used as the gas generating agent. 
Dicalcium phosphate was used as the channeling agent. The direct compression method 
was employed for preparation of the bilayer tablets. Various physicochemical 
parameters were evaluated for the prepared tablets. 
Atram et al., (2009)
13
 reported thatbilayer tablets of Amlodipin Besylate and 
Metoprolol Succinate were formulated for the management of hypertension. In the 
formulation of IR layer, SSG and pregelatinised tarch were used as superdisintegrant 
and was directly compressed. For SR portion, HPMC were used in granulation stage 
and also extra granularly. In vitro drug release of the optimized formulation showed 
9.96%, 35.56%, 52.12%, 90.46% release for Metoprolol Succinate in 1, 4, 8, 20 hrs 
respectively. However, Amlodipine Besylate released 98.28% at the end of 30 minutes. 
Nagaraju R
 
et al., (2009)
14
 developed formulation and evaluation of bilayer sustained 
release tablets of salbutamol and theophylline. Salbutamol and theophylline are 
available in conventional dosage forms, administered four times a day, leading to saw 
tooth kinetics and resulting in ineffective therapy. The combination of these two drugs 
in a single dosage form will enhance the patient compliance and prolong 
bronchodilation. In-vitro dissolution studies were carried out for all the bi-layered 
tablets developed using USP dissolution apparatus type 2 (paddle). In-vitro dissolution 
studies were carried out for all the bi-layered tablets developed using USP dissolution 
apparatus type 2 (paddle). 
Gohel MC et al., (2010)
15
 investigated were to achieve immediate release of 
paracetamol and tailored release of diclofenac sodium from bi-layer tablets and were 
prepared by using hydroxypropyl methyl cellulose as a matrixing agent. The analysis 
showed that the friability of paracetamol was distinctly influenced by the formulation 
variables. The bi-layer tablets shown immediate release of Paracetamol and modified 
release of diclofenac. 
 
Naeem MA et al., (2010)
16 
developed bilayer tablet formulations of Tramadol HCl 
(TmH) and acetaminophen (AAP) microparticles Coacervation via temperature change 
was the encapsulated method used for the preparation of the microparticles, with ethyl 
cellulose (EC) of medium viscosity as the polymer for extending drug release. The 
physicochemical compatibility and stability of the tablets were determined by Fourier 
transform infrared spectroscopy (FTIR), x-ray diffractometry (XRD), differential 
scanning calorimetry DSC) and thermogravimetric analysis (TGA). Microencapsulated 
TmH and AAP can be developed into suitable bilayer tablets that are stable and capable 
of releasing the drugs over 12 h. 
 
 
 
 
REVIEW OF DRUG & POLYMER 
Yamsani Madhusudan Rao et al (2010)
17
.,  Reported that formulated Bilayer tablets 
provided immediate release of glimepiride and metformin HCl as sustained release over 
a period of 8 hours.The immediate release layer was prepared using sodium starch 
glycolate as super disintegrant and sustained release using HPMC K4M and sodium 
carboxy methyl cellulose as polymers and PVP K30 as binder. Formulations containing 
higher concentration of sodium starch glycolate and SCMC in IR and SR layer 
respectively were optimised for bilayer tablets. 
Kumaresan C. et al., (2010)
18
 developed once a daily fixed triple combination of 
antidiabetic drugs wherein Pioglitazone and glimepiride are as immediate release and 
metformin is as extended release indicated suitability for patient compliance and 
stability. The tablets were prepared using wet granulation, compression and drug 
coating technique. The best formula was selected by physical evaluation of tablets, 
comparative dissolution profiles and stability. 
Durga Prasad Pattanayak et al., (2011)
19
 reported that Bilayer matrix tablet 
containing 1mg glimepiride as immediate release and 502mg mg of metformin HCl as 
sustained release was designed and evaluated by using same analytical technique. 
HPMC and PEO were used as polymer to get the sustained release profile over a 24hrs. 
The best formula was selected by physical evaluation of tablets, comparative 
dissolution profiles and Pharmacokinetic studies of various formulations of metformin 
hydrochloride and glimepiride.  
Sahu M et al., (2010)
20
 Reported that the designed inlayered tablet of glimepiride as 
immediate release and metformin hydrochloride as sustained release indicated 
suitability for patient compliance. Inner core portion was designed using 
superdisintegrants for immediate release and outer cup portion was designed using 
polymers such as HPMC and PVP to modulate drug release. 
J. Bagyalakshmi et al., (2011)
21
 Reported that bilayer matrix tablet containing 500mg 
of metformin HCl as SR from one layer and 5mg glipizide as IR from another layer can 
be prepared by solid dispersion method. Solubility of glipizide was increased by solid 
 
dispersion technique with sodium starch glycolate using kneading technique. Metformin 
was formulated using different grades of HPMC. 
Manoranjan S et al., (2010)
22
 Concluded that modified Inlayered tablet containing 
glimepiride as immediate release and metformin as sustained release was designed to 
improve oral therapeutic efficacy. Tablet compressing was done with core rod tooling 
where only one surface of core is exposed to outside and other drug is incorporated in 
cup portion. Common analytical method was developed for quantitative combined drug 
estimation. 
N. N. Rajendran et al., (2011)
23
 Concluded that Bilayer tablets of Metformin HCl and 
Pioglitazone HCl as an alternative to the conventional dosage form. Sustained layer of 
metformin were prepared by wet granulation method using different viscosity grade of 
HPMC as polymers and immediate release layer were prepared by direct compression 
using superdisintegrants such as SSG and Croscarmellose sodium. The result showed 
that combinations of polymers HPMC K100M and HPMCK4M in sustained layer can 
control the release of drug. 
Kotta Kranthi Kumar et al., (2010)
24
 Reported that Bilayer tablets of Metformin 
Hydrochloride and gliclazide was successfully formulated and evaluated. The 
investigation was aimed to the development of bilayered tablets of metformin 
hydrochloride and gliclazide as sustained release by using HPMC as retardant. The best 
formula was selected by physical evaluation of tablets, comparative dissolution profiles 
and similarity factor correlation studies of various formulations of metformin 
hydrochloride and gliclazide.  
Laxmi Goswami et al., (2010)
25
 Concluded that formulated floating bilayer tablets of 
metformin and pioglitazone remain buoyant over a period of 12-20 hours and released 
more than 80% of drug. The tablets were formulated by modified direct compression 
using polymers like HPMC, carbopol, PVP to facilitate immediate release of 
pioglitazone and sustained release of metformin and were subjected to various 
evaluation parameters including floating lag time, floating duration, drug content and 
spectrophotometric simultaneous estimation. 
AR Mullaicharam et al., (2010)
26
 Developed once daily sustained release matrix 
tablets of metoprolol tartrate with inlay hydrochlorthiazide tablet as immediate release. 
Both the layers were prepared by wet granulation method. Five trial batches of 
sustained release granules were prepared using HPMC in various percentages and one 
optimum formulation was selected among them on basis of in vitro dissolution studies. 
Chitra. P et al., (2011)
27
   Formulated and optimized once daily sustained release inlay 
tablet of propranolol hydrochloride and hydrochlorthiazide.SR active ingredient is 
selected from higher dose and IR active ingredient is selected from lower dose. Tablets 
were evaluated for hardness, thickness, uniformity of weight, friability, content 
uniformity, in-vitro drug release. Optimized formulation could extend release of PRO 
for 24 hrs and HCTZ for 15 mins. 
Tapan Kumar Pal et al., (2007)
28
 Concluded that the study helped in finding optimum 
formulation of Metformin HCl with sustained drug release. Tablets were prepared by 
non-aqueous wet granulation method using HPMC K15M as matrix forming polymer. 
Drug release profile was formulated using response surface methodology. % of drug 
released in 1hr, 8 hrs and time to 50% drug release. 
P. Jeyaprabha et al., (2010)
29
 Prepared a modified release tablet of gliclazide by using 
different grades of hydroxypropyl cellulose. Release process involved erosion and 
diffusion mechanism. Among all the 9 formulations prepared, formulation F9 with GXF 
15% cum EXF 12% had good release and highest f2 (56.9) value, therefore it was 
decided to comparable with innovator F1. 
Chinam Niranjan patra et al., (2007)
30 
developed a bilayer tablet of propranolol HCl 
using superdisintegrant SSG for the fast release layer and water immiscible polymers 
such as ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining layer. In 
vitro dissolution studies were carried out in a USP 24 apparatus I. The formulations 
gave an initial burst effect to provide the loading dose of the drug followed by sustained 
release for 12 h from the sustaining layer of matrix embedded tablets. In vitro 
dissolution kinetics followed the Higuchi model via a non-Fickian diffusion controlled 
release mechanism after the initial burst release.FT-IR studies revealed that there was 
no interaction between the drug and polymers used in the study. Statistical analysis 
(ANOVA) showed no significant difference in the cumulative amount of drug release 
after 15 min,but significant difference (p < 0.05) in the amount of drug released after 12 
h from optimized formulations was observed. 
Poonam S. Karekar et al., (2011)
31
 Proposed spectrophotometric method for the 
estimation gliclazide in bulk and pharmaceutical dosage form. Wavelength maxima for 
gliclazide was found to be 229.5nm with molar absorptivity of 1.4962×10
4
l/mol/cm. 
Beer‟s law was obeyed in the concentration range of 7-27 µg/ml. The limit of detection 
(LOD) and limit of quantification (LOQ) were found to be 0.31µg/ml and 0.92 µg/ml. 
Percentage recovery of drug for the proposed method ranged from 98.68-100.12% 
indicating no interference of the tablet excipients. 
Tanbir Ahammad et al., (2011)
32
 Prepared matrix tablets of gliclazide by direct 
compression and wet granulation process using Methocel K15M CR, studied effect of  
granulation process on drug release and found that wet granulation extend release more 
than that of direct compression technique. 
Chauhan Pratik Navinchandra et al., (2011)
33
 Developed mouth dissolving tablets of 
gliclazide using three super disintegrants hypromellose, crosspovidone and SSG at 
different concentrations with microcrystalline by direct compression. Among all the 
twelve formulations crosspovidone F6 emerged as overall best formulation due to its 
fast invitro dispersion when compared to other formulations and 97% drug release 
within 15 min. 
Raja Rajeswari K et al., (2011)
34
 Developed modified release hydrogel formulations 
of a poorly soluble drug, Gliclazide using a hydrophilic polymer HPMC in two grades 
i.e., HPMC 15cps and Methocel K4M. All six formulations were developed and 
evaluated for invitro drug release upto 16hrs and compared with that of marketed 
formulation. GMF VI was found to have similar release pattern proving to show 
controlled release following zero order release by anomalous diffusion. 
S. Chandra et al., (2011)
35
 Prepared fast dissolving tablets of gliclazide using solid 
dispersion and various concentrations of superdisintegrant agents like Ac-Di-Sol, 
Crospovidone, SSG by direct compression method. Among nine formulations, tablets of 
batch F6 containing Crospovidone and Avicel 102 showed super organoleptic 
properties along excellent invitro disintegration time and drug release as compare to 
other formulations. 
Mahendra labana et al., (2011)
36
 Designed modified release gliclazide by direct 
compression using HPMC as polymer, Dibasic calcium phosphate and maltodextrin as 
binder. The prepared formulations were further evaluated for hardness, friability, drug 
content uniformity, in vitro dissolution time and short term stability and drug excipient 
interaction were studied. 
Narendra Sharma et al., (2011)
37
 Developed second derivative spectrophotometric 
method for determination of metformin hydrochloride in bulk and in tablet dosage 
form. The quantitative determination of the drug was carried out using the second 
derivative values measured at 233.8 nm. Calibration graph constructed at 233.8 nm was 
linear in concentration range of 4-20 μg/ml with correlation coefficient 0.9979. The 
method was validated as per ICH guidelines and can be used for determination of 
Metformin hydrochloride in tablet dosage form. 
S A Patil et al., (2010)
38
 Formulated solid dispersion of metformin hydrochloride using 
methocel K100M as carrier by solvent evaporation and co grinding method. Solid 
dispersion with 1:4 and 1:5 ratio of drug to polymer obtained by solvent evaporation 
and cogrinding were selected as best candidates suitable for prolonged release oral 
dosage form of metformin. 
Dr K.L.Senthilkumar et al., (2011)
39
 Formulated and evaluated metformin sustain 
release tablets using different polymers as release retarding agent and concluded that 
formulation of sustained release tablet of metformin containing 13% HPMC K100 with 
binder PVP K30 was found to be ideal or optimized formulation of sustained release 
tablets for 10 hour release as it fulfils all the requirements for sustained release tablet. 
M. M. Varma et al., (2010)
40
 Designed gastroretentive floating drug delivery system of 
metformin hydrochloride using HPMC K4M and carbopol 934P as polymers and 
sodium bicarbonate as gas generating agent by wet granulation method. Release of 
metformin HCl from the floating tablets formulated with HPMC and /carbopol was 
slow and spread over 12 h and depended on % of polymer in the tablet. Batch F4 
(carbopol 934P 150 mg, sodium bicarbonate 50 mg) showed better sustained release 
than other formulations. 
N. Aruna et al., (2011)
41
 Formulated metformin HCl sustained release matrix tablet 
using Syzygium cumini as a release retarding agent which is antidiabetic in nature using 
various polymers HPMC K100M, Eudragit RLPO, Carbopol940, Ethyl cellulose by wet 
granulation method. Formulation containing HPMC K100M and ethyl cellulose showed 
sustained drug release pattern upto 12 hrs which matched drug release pattern of 
innovator. 
Sunil Kumar et al., (2011)
42
 Designed extended release metformin tablet by wet 
granulation method using HPMC K100M as polymer, stearic acid and IPA as binder. 
The prepared formulations were further evaluated for hardness, friability, drug content 
uniformity, in vitro dissolution time and for in vitro drug release pattern in pH 6.8 
phosphate buffer and short term stability and drug-excipient interaction were studied. 
Manju Nagpal et al., (2011)
43
 Developed oro-dispersible tablets of metformin by 
direct compression method using super disintegrants, effervescent and sublimation 
approach. Batch C4 prepared by effervescent approach was found to have the least 
disintegration time and maximum in vitro dissolution profile. 
Margret Chandira et al., (2010)
44
 Formulated extended release matrix tablet of 
metformin hydrochloride using different combinations of polymers HPMC K100M CR 
and carbopol 71 G by wet granulation method. Formulations F7, F9 and F10 containing 
HPMC K 100 M CR and Carbopol 71G in different concentration shows the extended 
drug release for up to 10 hrs, among these formulation, F10 is considered as optimized 
formulation because it shows similar drug release pattern with that of innovator. 
Harrower AD et al., (2009)
45
 Performed studies to assess the efficacy of various 
sulfonyl ureas in the management of diet failed NIDDM patients. The results showed 
that gliclazide is a potent hypoglycaemic agent having low incidence of side effects, 
few problems with hypoglycaemia and retains its efficacy longer than other 
sulfonylureas. 
Pareek et al., (2010)
46
 Evaluated efficacy and tolerability of metformin and gliclazide 
combination and found that addition of gliclazide to metformin is an effective treatment 
for inadequately controlled patients on sulfonyl urea or metformin alone and its 
combination achieves good glycemic control and improves lipid levels with better 
tolerability. 
 
 
 
DRUG AND EXCIPIENTS PROFILE 
METFORMIN HYDROCHLORIDE
47
: 
            Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line 
drug of choice for the treatment of type 2 diabetes, in particular, in overweight and 
obese people and those with normal kidney function. 
Chemical structure: 
 
IUPAC name: N,N-dimethylimidodicarbonimidic diamide 
Chemical formula: C4H11N5.HCl 
Molecular weight: 165.63 g/mol 
Category:  hypoglycemic 
Dose:   0.5 to 3 g daily, in divided doses 
PROPERTIES: 
Description:  white, crystalline powder hygroscopic 
Solubility: freely soluble in water; slightly soluble in ethanol (95%); 
practically insoluble in acetone, chloroform, dichloromethane 
and ether. 
Melting point: 222-226˚C 
Storage:  store in well closed container. 
MECHANISM OF ACTION: 
            Metformin improves hyperglycaemia primarily by suppressing glucose 
production by the liver. Metformin activates AMP-activated protein kinase (AMPK), an 
enzyme that plays an important role in insulin signalling, whole body energy balance, 
and the metabolism of glucose and fats. The mechanism by which biguanides increase 
the activity of AMPK remains uncertain; however, metformin increases the amount of 
cytosolic AMP.  In addition to suppressing hepatic glucose production, Metformin 
increases insulin sensitivity, enhances peripheral glucose uptake (by phosphorylating 
GLUT-4 enhancer factor), increases fatty acid oxidation and decreases absorption of 
glucose from the gastrointestinal tract. Increased peripheral utilization of glucose may 
be due to improved insulin binding to insulin receptors. 
Bioavailability  : 50 to 60% under fasting conditions 
Half life   : 6.2 hours 
Plasma protein binding : negligible 
Volume of distribution : 300 – 1000 L 
Metabolism   : none. 
Excretion   : active renal tubular excretion. 
CONTRAINDICATIONS 
 Hypersensitivity to drug. 
 Acute or chronic metabolic acidosis with or without coma. 
 Underlying renal dysfunction. 
 Heart failure requiring drug therapy. 
ADMINISTRATION 
 Administer with a meal. 
 Make sure patient swallows extended release tablets whole without crushing or 
chewing. 
 Don‟t administer extended release tablets to children. 
DOSING INFORMATION 
 Usual Adult Metformin Dose for Diabetes Mellitus Type II:  
            500 mg orally twice a day (with the morning and evening meal) 
 Extended Release: 
500 to 2000 mg orally once a day (with the evening meal). Maximum daily dose 
is 2500 mg. 
Adverse reactions 
            Diarrhoea, nausea, vomiting, abdominal bloating, abdominal cramping or pain, 
flatulence, anorexia. 
 
GLIMEPIRIDE
48
: 
It is a medium-to-long acting sulfonylurea anti-diabetic drug. It is sometimes 
classified as the first third-generation sulfonylurea,
[1]
 and sometimes classified as 
second-generation 
Structure: 
 
Molecular weight: 490.617 g/mol 
Molecular formula: C24H34N4O5S
 
 
Pharmacologic class: sulfonyl urea 
Therapeutic class: hypoglycaemic 
PROPERTIES: 
Description: White, hydrophobic powder 
Solubility: Practically insoluble in water, soluble in dimethylformamide, slightly 
soluble in methylene chloride, very slightly soluble in methanol. 
Melting point: 181
0
C 
Storage: store in well closed container. 
MECHANISM OF ACTION: 
Like all sulfonylurea, Glimepiride acts as an insulin secretagogue. It lowers 
blood sugar by stimulating the release of insulin by pancreatic beta cells and by 
inducing increased activity of intracellular insulin receptors. Not all secondary 
sulfonylurea have the same risks of hypoglycaemia. Glibenclamide (glyburide) is 
associated with an incidence of hypoglycaemia of up to 20–30%, compared to 2% to 
4% with Glimepiride. Glibenclamide also interferes with the normal homeostatic 
suppression of insulin secretion in reaction to hypoglycaemia, whereas Glimepiride 
does not have this property. Furthermore, glibenclamide diminishes the glucagon 
secretion in reaction to hypoglycaemia, whereas Glimepiride does not suppress this 
counter-regulatory reaction 
Half life: 5 hours 
Plasma protein binding   : >99.5%, highly bound to plasma proteins 
Metabolism: Extensively metabolized in the liver 
Excretion: Metabolites and conjugates are eliminated primarily by the kidneys (60-
70%) and also in the feces (10-20%). 
Indications: Type 2 Diabetes Mellitus 
Contraindications: 
 Hypersensitivity to Glimepiride or other sulfonylurea 
 Pregnancy 
Adverse effects: 
 Hypoglycaemia   
 Gastrointestinal disturbance (reported) 
 Skin reactions (rare) 
 thrombocytopenia (rare) 
 leukopenia  
 haemolytic anaemia         
SODIUM STARCH GLYCOLATE
 49
 : 
Nonproprietary Names : 
        BP         : Sodium Starch Glycollate 
        Ph Eur   : Carboxymethylamylum natricum 
        USPNF : Sodium starch glycolate 
Synonyms : Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; 
Primojel; starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
Chemical Name : Sodium carboxymethyl starch. 
Structural Formula : 
 
Molecular weight: 5×10
5 _ 
1×10
6  
Functional Category: Tablet and capsule disintegrant 
Applications in pharmaceutical formulation or technology: 
Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either direct 
compression or wet-granulation processes. The usual concentration employed in a 
formulation is between 2% and 8%, with the optimum concentration about 4%, 
although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of water 
followed by rapid and enormous swelling.  
Sodium starch glycolate has also been investigated for use as a suspending vehicle. 
Description: Sodium starch glycolate is a white to off-white, odourless, tasteless, free-
flowing powder.  
Typical Properties: Acidity / alkalinity: pH 3.0–5.0 or pH 5.5–7.5 for a 3.3% w/v 
aqueous dispersion. 
 
HYDROXY PROPYL METHYL CELLULOSE 
50
: 
Nonproprietary Names: 
       BP: Hypromellose 
       JP: Hydroxypropylmethylcellulose 
       PhEur: Hypromellosum 
       USP: Hypromellose 
Synonyms: Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
Methocel; methylcellulose propylene glycol ether; methyl 
hydroxypropylcellulose; Metolose; Tylopur. 
 
Chemical Name: Cellulose hydroxypropyl methyl ether 
Structural Formula: 
 
Functional Category: Coating agent; film-former; rate-controlling polymer for 
sustained release; stabilizing agent; tablet binder; 
viscosity increasing agent.                                 
Applications in pharmaceutical formulation or technology: 
It is widely used in oral, ophthalmic and topical pharmaceutical formulations. 
 Oral use - tablet binder, in film-coating, and as a matrix for use in 
Extended - release tablet formulations. 
 Ophthalmic use - added as a thickening agent to vehicles for eye drops 
and artificial tear solutions. 
 Topical use - emulsifier, suspending agent, and stabilizing agent in 
topical gels and ointments. 
Description: Hypromellose is an odourless and tasteless, white or creamy white 
fibrous or granular powder. 
Typical Properties: Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 Density (tapped): 0.557 g/cm
3 
 
Density (true): 1.326 g/cm
3
  
Solubility: soluble in cold water, forming a viscous colloidal 
solution 
 
XANTHAN GUM 
51
: 
Nonproprietary Names : 
          BP: Xanthan gum 
          PhEur: Xanthani gummi 
          USPNF: Xanthan gum 
Synonyms: Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; 
Vanzan NF; Xantural 
Chemical Name: Xanthan gum. 
Functional Category: Stabilizing agent; suspending agent; viscosity-increasing agent. 
Applications in pharmaceutical formulation or technology: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent.(3–5) It is also used as a 
thickening and emulsifying agent. 
Description: Xanthan gum occurs as a cream- or white-colored, odorless, free-
flowing, fine powder. 
Typical properties: Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution.             
Melting point chars at 270˚C.  
Solubility: practically insoluble in ethanol and ether; soluble in 
cold or warm water 
 
MICRO CRYSTALLINE CELLULOSE 
52
 : 
Nonproprietary Names: 
BP: Microcrystalline cellulose 
            PhEur: Cellulosum microcristallinum 
            USPNF: Microcrystalline cellulose 
Synonyms: Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; 
Vivapur. 
Chemical Name: Cellulose 
Empirical Formula: (C6H10O5)n 
Molecular weight: approx. 36,000 where n is approx 220.         
Structural Formula: 
 
 
Functional Category: Adsorbent; suspending agent; tablet and capsule diluent; 
tablet disintegrant. 
Applications in pharmaceutical formulation or technology: 
Binder/diluent in oral tablet and capsule formulations where it is used in both 
wet-granulation and direct-compression processes 
Description: Microcrystalline cellulose is a purified, partially depolymerized cellulose 
that occurs as a white, odorless, tasteless, crystalline powder composed 
of porous particles. 
Typical Properties: Density (bulk)   : 0.337 g/cm3 
Density (tapped): 0.478 g/cm3 
          Density (true)    : 1.512–1.668 g/cm3 
          Melting range    : chars at 260–270˚C. 
          Solubility: slightly soluble in 5% w/v sodium hydroxide solution; 
             practically insoluble in water, dilute acids, and most solvents 
MAGESIUM STEARATE 
53
 : 
Nonproprietary names: 
      BP/JP/USPF : Magnesium stearate. 
      Ph Eur           : Magnesii stearas. 
Synonyms: Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic 
acid, magnesium salt. 
Chemical name: Octadecanoic acid magnesium salt. 
Empirical formula: C36H70MgO4           
Molecular weight: 591.34 
Structural formula: [CH3(CH2)16COO]2Mg 
Functional Category: 
             USP:  Tablet and capsule lubricant. 
             BP/EP: lubricant, pharmaceutical aid. 
             Others: Glidant, anti-adherent. 
 
Applications in pharmaceutical formulation or technology: 
Tablet and capsule lubricant, glidant or anti-adherent. 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic 
acid and a characteristic taste. 
Typical Properties: Density (bulk): 0.159 g/cm3 
          Density (tapped): 0.286 g/cm3 
          Density (true):  1.092 g/cm3 
          Melting range: 126–1308C (high purity magnesium 
stearate) 
Solubility: Practically insoluble in ethanol, ether and water; 
slightly     
      soluble in warm benzene and ethanol (95%).            
 
TALC 
54
 : 
Nonproprietary names: 
           BP      : Purified talc                         
           JP       : Talc 
           PhEur : Talcum 
           USP    : Talc 
Synonyms: Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil 
Osmanthus; Magsil Star; powdered talc; purified French chalk; Purtalc; 
soapstone; steatite; Superiore. 
Chemical name: Talc 
Empirical Formula:  Mg6(Si2O5)4(OH)4 
Molecular Weight: 379.3 g/mol   
Functional Category: Anticaking agent; glidant; tablet and capsule diluent; 
tablet and capsule lubricant 
 
Applications in pharmaceutical formulation or technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. In topical preparations, talc is used as a dusting powder, although it should not 
be used to dust surgical gloves. Talc is additionally used to clarify liquids and is also 
used in cosmetics and food products, mainly for its lubricant properties. 
Description: is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch 
and free from grittiness. 
Typical properties: Acidity/alkalinity: pH 7–10 for a 20% w/v aqueous dispersion. 
              Solubility            : Practically insoluble in dilute acids and alkalis, 
                                                  organic solvents, and water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND PLAN OF WORK 
Metformin is an oral antidiabetic biguanide drug for the treatment of type 2 diabetes, in 
particular, in overweight and obese people and those with normal kidney function. It is 
a class III high soluble, low permeable compound slowly and incompletely absorbed 
from the gastrointestinal tract and the absolute bioavailability of a single 500mg dose is 
reported to be 50%-60%. The compound also has relatively short plasma elimination 
half-life of 1.5 to 4.5 hrs, hence Metformin HCl has to be administered two or three 
times per day. Glimepiride is one of the third generation sulfonylurea drugs useful for 
control of diabetes. It maintains a more physiologic regulation of insulin secretion and 
the risk of hypoglycaemia is less than with other sulfonylurea. It‟s a white hydrophobic 
powder, practically insoluble in water; bioavailability is 100%, half-life is 5 hrs and 
available dose is generally 1mg or 2mg once a day. Glimepiride and Metformin 
simultaneously targets insulin resistance and insulin deficiency type II diabetes. 
The aim is to develop a combination drug therapy for anti diabetic tablet formulation 
having different mechanism of action to complement each other and together 
effectively lower blood glucose level. The immediate release layer of Glimepiride is 
prepared by direct compression method using SSG as superdisintegrant with other 
excipients and sustained release layer of Metformin HCl are prepared by wet 
granulation method using HPMC and Xanthan Gum as polymer in different 
concentration with other excipients 
PLAN OF WORK 
1. To carry out brief literature review 
2. Drug excipients compatibility studies by FT-IR 
3. Formulation of granules for compression 
4. Precompression evaluation 
5. Formulation of Bilayer tablets 
6. Postcompression evaluation  
7. Pharmacokinetic study 
8. Stability study 
 
 
EXPERIMENTAL 
MATERIALS USED: 
Table 2 :  
Name of the materials Use in formulation Manufacturers 
Metformin HCl Active ingredient Arti Drugs Ltd. 
Glimepiride Active ingredient Enaltec Labs Pvt. Ltd. 
HPMC K100M Hydrophilic polymer Shin_ETSU Chemicals Ltd. 
Xanthan gum Hydrophilic polymer Shin_ETSU Chemicals Ltd. 
Micro Crystalline 
Cellulose Avicel 
Directly compressible 
diluents 
Gujarat Microwax Pvt. Ltd. 
Sodium Carboxy Methyl 
Cellulose 
Hydrophilic polymer Shin_ETSU Chemicals Ltd. 
Iso propyl alcohol Binder Arti Drugs Ltd. 
Sodium starch glycolate Super disintegrants Maruti chemicals ltd 
Magnesium Stearate Glidant Vasa Pharmaceuticals Pvt Ltd 
Talc Lubricant Gujarat Microwax Pvt. Ltd. 
Col. Brilliant blue lake Dye Narmada Food and Drugs Ltd 
 
 
 
 
 
 
INSTRUMENTS USED: 
Table 3:  
S. 
No. 
Instrument Manufacturer 
1 Electronic Balance Mettler Toledo, Mumbai 
2 
Rotary  tablet Compression 
Machine (10 stages) 
Cadmach, Ahmedabad 
3 Hardness Tester Electrolab, Mumbai  
4 Friability Test Apparatus Electrolab, Mumbai 
5 Vernier calliper Inox- somet, Japan 
6 
Dissolution apparatus. 
 
Lab India. (USP XX III) 
(DTD – 06P), Mumbai 
7 
Double beam UV 
Spectrophotometer 
Systronic corporation, 
Mumbai 
8 FTIR Spectrophotometer Shimadzu, Mumbai 
10 Digital pH meter Hanna instruments, Japan 
11 Hot Air Oven Kemi, Mumbai 
12 Melting point apparatus. Kemi, Mumbai 
13 Bulk density apparatus. Kemi, Mumbai 
 
PREFORMULATION STUDIES: 
Preformulation studies are the first step in the rational development of dosage form. It is 
an investigation of physical and chemical properties of a drug substance alone and 
when combined with excipients. Preformulation investigations are designed to identify 
those physicochemical properties and excipients that may influence the formulation 
design, method of manufacture and pharmacokinetic-biopharmaceutical properties of 
the resulting product. Following are the test performed for the preformulation study. 
 
Drug and Excipients compatibility studies
55, 56
: 
Physical compatibility studies by FTIR: 
The active ingredients and polymer (1:1) were mixed and taken in 2 ml glass vials and 
sealed. Then these glass vials were kept at room temperature and 40
0
C/75%RH for 
about 1 month. The physical compatibility evaluation was performed in visual basis. 
The study implies that the drug, polymer and other excipients were physically 
compatible with each other as there was no change of physical description. The results 
have been shown in the Table 4. 
Table 4: Drug–Excipients Physical compatibility studies 
S.No Drug + 
Excipients 
Description at initial day RT,40
0
C/75%RH 
In days 
10
th 
20
th 
30
th 
1 MH White, Crystalline powder NC NC NC 
2 GL White, Crystalline powder NC NC NC 
3 XG Creamy yellow crystalline powder NC NC NC 
4 HPMC K100M White, creamy crystalline powder NC NC NC 
5 SSG White, free-flowing hygroscopic 
powder 
NC NC NC 
6 MCCP White, crystalline powder NC NC NC 
7 Mg. Stearate White, crystalline powder NC NC NC 
8 Talc White or greyish white powder NC NC NC 
9 MH+GL White, Crystalline powder NC NC NC 
10 MH+GL+XG White, crystalline powder NC NC NC 
11 MH+GL+HPMC White, crystalline powder NC NC NC 
12 MH+GL+SSG White, crystalline powder NC NC NC 
13 MH+GL+All 
Exipients 
White, crystalline powder NC NC NC 
 
MH-Metformin HCl, GL-Glimepiride, XG-Xanthan gum, HPMC K100M-Hydroxy 
propyl methyl cellulose Grade, SSG-Sodium starch glycolate, MCCP-Microcrystalline 
cellulose powder  
Chemical compatibility studies by FTIR: 
IR spectra of drug and polymers and all super disintegrants alone and along with drug  
in KBr pellets at moderate scanning speed between 4000-400cm
-1
 was carried out using 
FTIR. The peak values and the possibility of functional groups shown in spectra (Table 
4 & 5) were compared with standard values and shown below Fig 4 to 8.  
Chemical compatibility studies by FT-IR: 
 
Fig 4: FT-IR spectra of Glimepiride 
 
Fig 5: FT-IR spectra of Glimepiride + Sodium starch glycolate 
 Fig 6: FT-IR spectra of Metformin HCl 
 
Fig 7: FT-IR spectra of Metformin HCl + HPMC 
 
Fig 8: FT-IR spectra of Metformin HCl + Xanthan gum 
Table 5: Interpretation of FT-IR spectra of Glimepiride  
S. 
no 
Functional 
group 
Assessment 
peaks 
1 N-H Amine 3367 
2 C-H Aromatic 2931 
3 C=O Amide 1708.17 
4 C=C Aromatic 1543.10 
5 Sulfoxides 1080 
 
Table 6: Interpretation of FT-IR spectra of Metformin HCl 
S. 
no 
Functional 
group 
Assessment 
peaks 
1 C-H Alkanes 1458, 1381 
2 C-H Strech 2885 
3 N-H Amide 3200 
 
Standard curve of Metformin HCl 
100 mg of metformin HCl was dissolved in 100 ml of phosphate buffer pH 6.0 (stock 
solution). From the stock solution aliquots of 10, 20, 30, 40, 50 ml were pipetted out 
and made up to 100 ml with buffer. The absorbance of above solution was measured at 
254 nm by UV spectrometer. 
Correlation coefficient value indicates there is a linear correlation between 
concentration and absorbance. Metformin HCl obeys the beers law in concentration 
range of 10-100 µg/ml at 254 nm. 
Table 7:  
   
Fig 9: Calibration curve of Metformin                   
HCl 
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10 0.281 
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40 1.119 
50 1.387 
Preparation of Bi layer tablets 
Formula of immediate release Glimepiride: 
Composition of the immediate release layer is given in Table 7. The final weight of the 
immediate release layer was fixed to 200 mg. An immediate release Glimepiride layer 
was prepared by direct compression. Accurately weighed quantity of Glimepiride, MCC 
and SSG were passed through sieve 40, mixed with brilliant blue lake which is passed 
from sieve 100. Add talc to above, rotate for 3 minutes at 20 rpm. Magnesium stearate 
was shifted through sieve 30 and blended with the final screened granules for 5 min at 
20 rpm. 
Table 8: Formula of immediate releasing layer 
Ingredients 
Quantity 
(mg) 
Glimepiride 1 
MCCP Avicel 188 
SSG 6 
Mg stearate 2 
Talc 2 
Brilliant blue lake 1 
Total Weight of 1 tablet 200 
Formula of sustained release Metformin HCl granules: 
Compositions of different trial formulations for the sustained release layer are given in 
Table 8. Different batches of Metformin HCl sustained release layer (F1 to F6) were 
prepared with varying concentrations of different polymer by wet granulation method. 
Accurately weighed quantity of Metformin HCl, Micro Crystalline Cellulose, HPMC 
K100M, Sodium Carboxy Methyl Cellulose, Xanthan gum and talc were sieved using 
screen 22. The screened powders were then transferred into the rapid mixer granulator 
and mixed for 5 min. Binder solution of IPA were prepared. The dry mix was 
granulated by the above binder solution. Impeller was kept at 200 rpm. One to two 
minute binder addition and three min kneading without chopper was used to get desired 
granules. Drying of wet granules was carried out in rapid dryer (Retch rapid dryer, 
Germany) at temperature 50
0
C and air flow at 60%. Final dried granules were passed 
through screen 20. Extra granular magnesium stearate was sifted through screen 40 and 
added to the above blend in blender and mixed for 3 min at 20 rpm. 
Table 9: Formula of sustaining layer. 
Ingredients 
Quantity (mg) 
F1 F2 F3 F4 F5 F6 
Metformin HCl 504 504 504 504 504 504 
Sodium Carboxy 
Methyl Cellulose 
50 50 50 50 50 50 
HPMCK100M - - - 150 200 250 
Xanthan gum 150 200 250 - - - 
MCC 120 70 20 120 70 20 
Iso propyl alcohol q.s q.s q.s q.s q.s q.s 
Talc 5 5 5 5 5 5 
Magnesium 
stearate 
20 20 20 20 20 20 
Total wt 850 850 850 850 850 850 
 
Pre compression Studies of granules 
57, 58
: 
1. Bulk Density (Db): 
It is the ratio of total mass of powder to the bulk volume of powder. It was measured by 
pouring the weight powder (passed through standard sieve # 20) into a measuring 
cylinder and initial weight was noted (Table 12) and calculated according to the 
formula mentioned below. It is expressed in g/ml and is given by 
                                          Db = M/ Vb  
                          Where, M - mass of powder 
                                       Vb - bulk volume of the powder. 
 
2. Tapped Density (Dt): 
Volume was measured by tapping the powder for 750 times and the tapped volume was 
noted if the difference between these two volumes is less than 2%. If it is more than 
2%, tapping is continued for 1250 times and tapped volume was noted (Table 12). It is 
expressed in g/ml and is given by 
                                        Dt = M / Vt 
                      Where, M - mass of powder 
                                   Vt - tapped volume of the powder. 
3. Angle of Repose (): 
It is defined as maximum angle possible between the surface of the pile of powder and 
the horizontal plane 
                                                   = tan
-1
 (h / r) 
                         Where, - angle of repose. 
                                      h - height in cms 
                                      r - radius in cms. 
The powder mixture was allowed to flow through the funnel fixed to a stand at definite 
height (h). The angle of repose was then calculated by measuring the height and radius 
of the heap of powder formed (Table 12). Care was taken to see that the powder 
particles slip and roll over each other through the sides of the funnel. Relationship 
between angle of repose and powder flow property. 
Table 10: Angle of Repose as an Indication of Powder Flow Properties 
S. 
No. 
Angle of 
repose 
Type of 
flow 
1 ˂20 Excellent 
2 20-30 Good 
3 30-34 Passable 
4 ˃34 Very poor 
 
4. Carr’s index (or) % compressibility: 
It indicates powder flow properties. It is expressed in percentage and is give 
                                               Dt – Db 
                                     I =    ------------ ×100 
                                                     Dt 
                            Where, Dt - tapped density of the powder and 
  Db - bulk density of the powder. 
 
Table 11: Relationship between % compressibility and flow ability 
Percentage 
compressibility 
Flow ability 
5-12 Excellent 
12-16 Good 
18-21 Fair passable 
23-35 Poor 
33-38 Very poor 
˂40 Very very poor 
 
5. Haussner’s ratio: 
Hausner‟s ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula (Table 12). 
                                                                                 Dt 
                                                Hausner’s ratio = ------- 
                                                                                 Db 
 
Where, Dt - tapped density, Db - bulk density. 
Lower Hausner‟s ratio (<1.25) indicates better flow properties than higher ones (>1.25). 
Table 12: Precompression study  
S. 
no 
Parameters 
Formulation 
type 
Formulation code 
F1 F2 F3 F4 F5 F6 
1 Angle of repose 
Immediate 
Release layer 25.68 26.1 24.86 25.57 26.46 25.52 
Sustained 
Release layer 31.58 30.7 32.71 29.52 27.81 28.14 
2 
Bulk density 
(gm/cm
2
) 
Immediate 
Release layer 0.454 0.448 0.452 0.461 0.451 0.453 
Sustained 
Release layer 0.57 0.556 0.54 0.567 0.548 0.58 
3 
Tapped density 
(gm/cm
2
) 
Immediate 
Release layer 0.523 0.512 0.538 0.517 0.511 0.512 
Sustained 
Release layer 0.661 0.658 0.642 0.661 0.635 0.671 
4 Hauser‟s ratio 
Immediate 
Release layer 1.15 1.14 1.19 1.10 1.13 1.13 
Sustained 
Release layer 1.15 1.18 1.18 1.16 1.15 1.15 
5 
Compressibility 
index (%) 
Immediate 
Release layer 13.19 12.5 15.98 9.80 11.74 12.10 
Sustained 
Release layer 13.76 15.50 15.62 14.22 13.70 13.43 
 
COMPRESSION OF BILAYER TABLET: 
Compression of bilayer tablets were done by using Cadmach double rotary bi-layer 
compression machine (Cadmach, Ahmedabad). The prepared granules of each layer 
were compressed using 19.00 × 9.00mm, ‘D’ tooling standard concave, flat faced 
modified capsule shaped punch. The hardness was kept between 9-12kp. Both the 
prepared granules came from two different hoppers to two different feed frames 
where they occupied the die cavity. The bottom or first layer of Metformin HCl was 
compressed first with lower pressure, which was then followed by filling of the die 
cavity by the second layer Glimepiride. The final compression was done only after both 
the granules occupied the die cavity one on top of the other. Both the layers were 
identified on the basis of colour since the immediate release layer had blue colour and 
the sustain release layer is white colour (Fig 10).  
Table 13: Punches specification 
S. no Punch parameters 
1 Punch diamension 19 X 9 mm 
2 Punch shape Concave 
3 Upper punch Break line 
4 Lower punch Plane 
 
              
Fig 10: Photograph of prepared bilayer tablets 
POST COMPRESSION STUDIES OF TABLETS
61, 62
: 
Weight variation: 
Twenty tablets were selected randomly from the lot and weighed individually to check 
for weight variation and average weight was calculated. The deviation of each tablet 
from average weight was calculated and percent deviation was computed. Weight 
variation specification as per I.P. is shown in (Table 14). The tablet compression 
machine was suitably in tune to produce tablets of uniform weight. 
Table 14: Weight Variation Specification as per IP 
Average weight of 
tablet 
Percent 
deviation 
80 mg or less ±10 
More than 80 mg but 
less than 250mg 
±7.5 
250 mg or more ±5 
Thickness: 
The thickness in millimeters was measured individually for 10 preweighed tablets by 
using vernier calipers. The average thickness was reported. Thickness may affect the 
hardness, disintegration time and dissolution rate (Table 15). 
Hardness: 
Tablet hardness was measured using electrolab hardness tester. The crushing strength of 
the 10 tablets with known weight and thickness of each was recorded in kilopond (kp) 
and the average hardness was reported. Tablets hardness was checked at the start and 
during the compression process to control an acceptable range of tablet hardness (Table 
15).  
Friability (F): 
Twenty tablets were selected from each batch and weighed. Each group of tablets was 
rotated at 25 rpm for 4 min (100 rotations) in the electrolab tablet friabilator. The tablets 
were then dust and re-weighed to determine the loss in weight. Friability was then 
calculated as percent weight loss from the original tablets. The friability (F) is given by 
the formula (Table 15). 
                                                     Initial wt – Final wt 
                                             F =      ---------------------   × 100 
                                                            Initial wt 
Table 15: Post compression parameters 
S. 
no 
Parameters 
Formulation 
F1 F2 F3 F4 F5 F6 
1 Weight variation
  
(mg)
 
1060.5 1059.2 1051.9 1062.4 1055.8 1056.2 
2 Thickness (mm) 6.63 6.69 6.70 6.78 6.71 6.70 
3 Hardness (kg/cm
2
) 10.1 9.8 10.2 10.4 9.9 10.1 
4 Friability (%) 0.46 0.49 0.44 0.51 0.46 0.51 
5 
Content 
Uniformity (%) 
IR 98.81 99.25 99.35 98.77 99.86 99.98 
SR 99.92 98.8 99.67 99.57 99.01 99.24 
Drug content of bilayer tablet  
For Metformin HCl 
Preparation of phosphate buffer pH 6.0:  
Weigh accurately about 6.8 gm of potassium dihydrogen orthophosphate in 1000 ml 
beaker, add sufficient water to dissolve and make up the volume with water. Adjust pH 
6.0 with 1 M sodium hydroxide. 
Standard preparation:  
Weigh accurately about 50mg of Metformin HCl WS in 100ml volumetric flask, add 
50ml of phosphate buffer pH-6 to dissolve with the aid of ultrasound and make volume 
100ml with phosphate buffer pH-6. Transfer 1ml of this solution to 100ml volumetric 
flask and make volume 100ml with phosphate buffer pH-6. 
Sample preparation: 
Crush the content of 20 tablets to a fine powder and weigh equivalents to 50 mg of 
Metformin HCl to 100 ml volumetric flask, add 50 ml of phosphate buffer pH-6.0 to 
dissolve with the aid of ultrasound and make volume 100 ml with phosphate buffer pH-
6.0. filter the solution through Whatman filter paper no.(1). Transfer 1 ml of this 
solution to 100 ml volumetric flask and make volume 100 ml with phosphate buffer pH-
6.0.Measure the absorbance of standard and sample solution at about 254 nm using 
phosphate buffer pH-6.0 as a blank in the reference cell.     
                            spl abs     std wt         1         100          100     avg wt          
Amount of MH= --------X-- ------- X ------ X--------- X ------- X--------X potency 
                            std abs       100         100      spl wt         1          100   
For Glimepiride: 
Preparation of buffer: 
Dissolve 1.5 gm of potassium dihydrogen phosphate in 500 ml of distilled water. 
Adjusted the pH with phosphoric acid. 
Preparation of mobile phase: 
Prepare a mixture of buffer and acetonitrile in the ratio of 800:200 respectively. Degas 
for 15 minutes and filter the mobile phase through 0.22 µ filter. 
Diluents:  0.1 M Methanolic hydrochloride. 
Chromatographic conditions: 
Column  : waters symmetry C8 (100mm X 4.0 mm), 5 µ or Equivalent 
Flow rate  : 1.0 ml / minute 
Wavelength  : 276 nm 
Injection volume : 20 µl 
Column temperature : 40
0
 C 
Standard preparation: 
Weigh accurately about 50 mg of Glimepiride WS to 100 ml volumetric flask, add 50 
ml of diluent to dissolve with the aid of ultrasound and make volume with diluents. 
Transfer 10 ml of this solution to 50 ml volumetric flask and make volume with 
diluents. 
Sample preparation: 
Crush the content of 20 tablets to a fine powder and weigh accurately quantity of 
powder equivalent to about 5 avg weight( equivalent to 5 mg of glimepiride) of tablet to 
a 50 ml volumetric flask, add 25 ml of diluents to dissolve with the aid of ultrasound 
and make volume with diluents. Filter the solution through whatman filter paper no. 1.                                                                                                                                       
                            spl area    std wt      10 ml      50 ml      avg wt                      100             
% content uniformity= -------X---------- X----------X---------X---------X potency X----- 
                             std area    100 ml     50 ml      spl wt      100                         L.C  
 
In-vitro dissolution studies of bilayer tablet: 
Dissolution study of sustained release and immediate release of different tablet 
formulations were carried out separately. 
Dissolution of sustained release tablet: 
Preparation of phosphate buffer pH 6.0:  
Weigh accurately about 6.8 gm of potassium dihydrogen orthophosphate in 1000 ml 
beaker, add sufficient water to dissolve and make up the volume with water. Adjust pH 
6.0 with 1 M sodium hydroxide.  
Dissolution conditions:         
Apparatus : USP Type II (Paddle type) 
            Medium : 6.0 pH phosphate buffer 
            Rpm  : 50 
            Volume : 900ml 
            Temp  : 37.5°C 
Standard preparation:  
Weigh accurately about 50mg of Metformin HCl WS in 100ml volumetric flask, add 
50ml of dissolution medium to dissolve with the aid of ultrasound and make volume 
100ml with dissolution medium. Transfer 2 ml of this solution to 100ml volumetric 
flask and make up volume with dissolution medium. 
Procedure: 
The study was carried out for 12 hours. 20 ml of samples were withdrawn at the time 
interval of 1, 2, 4, 6, 8, 10
th 
hour from the zone midway between the surface of the 
dissolution medium and top of the paddle, not less than 1 cm from the vessel wall. Filter 
through whatman filter paper no. 1. Transfer immediately 20 ml of dissolution medium 
to bowls to maintain the volume of medium. Transfer 2 ml of this filtrate to 100 ml 
volumetric flask and make volume with dissolution medium.Measure the absorbance of 
standard and sample solution at about 254 nm using dissolution medium as a blank in 
reference cell. 
The percentage of Metformin HCl release was calculated using following formula. 
                             Spl. abs   std wt      2 ml     900 ml     100 ml    1                          100 
% of metformin = --------X ------- X------- X-------- X--------- X----- X potency X----- 
                             Std. abs   100 ml   100 ml       1          2 ml       100                      L.C 
 
 
Dissolution of immediate release tablet: 
Preparation of phosphate buffer pH 5.6: 
Weigh accurately about 6.8 gm of potassium dihydrogen orthophosphate in 1000 ml 
beaker, add sufficient water to dissolve and make up the volume with water. Adjust pH 
5.6 with 1 M sodium hudroxide. 
Preparation of mobile phase: 
Prepare a mixture of buffer and acetonitrile in the ratio of 800:200 respectively. Degas 
for 15 minutes and filter the mobile phase through 0.22 µ filter. 
Diluents: 0.1 M Methanolic hydrochloride.  
Dissolution conditions:         
Apparatus:   USP Type II (Paddle type) 
            Medium    :   5.6 pH phosphate buffer 
            Rpm          :   50 
            Volume     :   900ml 
 Temp        :    37.5°C 
Chromatographic conditions: 
 Column  : waters symmetry C8 (100mm X 4.0 mm), 5 µ or Equivalent 
 Flow rate             : 1.0 ml / minute 
 Wavelength             : 276 nm 
 Injection volume : 20 µl 
 Column temperature : 40
0
 C 
Standard preparation: 
Weigh accurately about 50 mg of Glimepiride WS to 100 ml volumetric flask, add 50 
ml of diluents to dissolve with the aid of ultrasound and make volume with diluents. 
Transfer 10 ml of this solution to 100 ml volumetric flask and make volume with 
diluents. Further transfer 2 ml of this solution to 100 ml volumetric flask and make up 
volume with phosphate buffer pH 5.6. 
Procedure: 
Dissolution studies were carried out by USP paddle method Type II apparatus at 37± 
0.50 ° c, taking 900ml of phosphate buffer pH 5.6 as a dissolution medium. Speed of 
rotation of paddle was set at 50rpm. Withdrawn 20 ml of solution from the zone 
midway between the surface of the dissolution medium and top of the paddle, not less 
than 1 cm from the vessel wall. Filter through whatman filter no. (1). Samples were 
suitably diluted and analyzed. The percentage release was calculated. 
                           spl. area   std. wt    10 ml    2 ml     900 ml     1                           100 
% of Metformin=  ----- X ------- X ------ X -------X-------- X ----- X potency X-------- 
                           std.area   100 ml    100 ml  100 ml     1          100                         L.C 
 
 
Table 16: In-vitro dissolution profile of formulation F1 to F6 
Time Formlulation 
type 
Cumulative % of drug release 
F1 F2 F3 F4 F5 F6 
(Min)   
5 
Immediate 
Release layer 
54.79 57.15 56.67 56.40 56.15 57.26 
10 71.12 71.10 70.88 73.24 68.66 72.43 
20 89.46 89.73 90.03 92.02 89.62 90.27 
30 99.06 99.33 99.00 101.55 100.93 99.80 
(hours)   
1 
Sustained 
Release layer 
25.91 22.48 24.52 30.51 25.13 26.40 
2 51.34 38.37 35.27 56.82 56.91 41.81 
4 73.58 51.67 59.10 69.34 68.64 62.48 
6 89.34 76.18 74.26 86.91 83.40 76.94 
8 104.51 81.69 82.45 98.12 91.57 87.81 
10  87.91 89.48  97.24 99.53 
 
 
Fig 11: In-vitro drug release of  Sustained Release layer of formulation F1 to F6 
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 Fig 12: In-vitro drug release of Immediate Release layer of formulation F1 to F6 
 
KINETIC ANALYSIS 
63, 64. 
The results of in vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows: -  
1. Zero - order kinetic model - Cumulative % drug released versus time. 
2. First – order kinetic model - Log cumulative percent drug remaining versus 
time. 
3.  Higuchi‟s model - Cumulative percent drug released versus square root of time. 
4. Korsmeyer equation / Peppa‟s model - Log cumulative percent drug released 
versus log time. 
5. Hixon and Crowell erosion equation – cube root of drug remaining Vs time in 
hrs 
 
Zero order kinetics:  
Zero order release would be predicted by the following equation: - 
 At = A0 – K0t 
Where,  
 At  = Drug release at time „t‟. 
 A0 = Initial drug concentration. 
  K0 = Zero - order rate constant (hr
-1
). 
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When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys Zero – order kinetics and its slope is equal to Zero order 
release constant K0. 
First Order Kinetics: 
First – order release would be predicted by the following equation: - 
Log C = log C0 – Kt / 2.303 
Where,  
C   = Amount of drug remained at time„t‟. 
C0 = Initial amount of drug. 
K   = First – order rate constant (hr-1). 
When the data plotted as log cumulative percent drug remaining versus time, yields a 
straight line, indicating that the release follow first order kinetics. The constant „K1‟ can 
be obtained by multiplying 2.303 with the slope value. 
Higuchi’s model: 
Drug release from the matrix devices by diffusion has been described by following 
Higuchi‟s classical diffusion equation: - 
Q = [Dε / τ (2 A - εCs) Cst] ½ 
Where, 
Q = Amount of drug released at time„t‟. 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = the solubility of the drug in the matrix. 
ε = Porosity of the matrix. 
τ = Tortuosity. 
t = Time (hrs) at which „q‟ amount of drug is released. 
Above equation may be simplified if one assumes that „D‟, „Cs‟ and „A‟ are constant. 
Then equation becomes: -         
   Q = Kt
1/2
 
When the data is plotted according to equation i.e. cumulative drug release versus 
square root of time yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to „K‟ (Higuchi‟s 1963). 
Korsmeyer equation / Peppa’s model:  
To study the mechanism of drug release from the sustained-release matrix tablets of 
valsartan, the release data were also fitted to the well-known exponential equation 
(Korsmeyer equation/ peppa‟s law equation), which is often used to describe the drug 
release behavior from polymeric systems. 
Mt / Mα = Kt
n 
Where, 
Mt / Mα = the fraction of drug released at time„t‟, K = Constant incorporating the 
structural and geometrical characteristics of the drug / polymer system, n = Diffusion 
exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, And we get: -  
   Log Mt / Mα = Log K + n Log t  
Table 17: Description of diffusion mechanism 
Diffusion 
exponent (n) 
Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n >0.89 Super case-II transport 
When the data is plotted as log of drug released versus log time, yields a straight line 
with a slope equal to „n‟. For Fickian release „n‟ = 0.45 while for anomalous (non - 
Fickian) transport „n‟ ranges between 0.45 and 1.0. 
Hixson and crowell cuberoot erosion equation: 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson and cowell rate equation. The graph 
was plotted by cube root of % drug remaining Vs time in hours. 
                  Q0
1/3
-Qt
1/3
=KHCt 
               Where  Qt      - amount of drug released in time t 
                           Q0     - initial amount of drug 
                           KHC  - rate constant for Hixson crowell equation        
Data obtained from in vitro release of metformin hydrochloride from the bilayer tablets 
were fitted in various kinetic models and results are tabulated in the Table No.   
 
                   
        Fig 13: Zero order plot           Fig 14: First order Plot  
 
           
Fig 15: Higuchi plot   Fig 16: Korsmeyer -Peppas plot 
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 Fig 17: Hixson crowell cuberoot plot 
 
 
Table 18: Results of kinetic study 
Formulation 
code 
Zero 
order
(R
2
) 
First 
order 
(R
2
) 
Higuchi’s 
kinetics 
(R
2
) 
Peppa’s kinetics Hixson 
Crowell’s 
kinetics(R
2
) R
2
 N 
F1 0.932 0.995 0.988 0.972 0.648 0.991 
F2 0.921 0.988 0.984 0.983 0.598 0.978 
F3 0.922 0.998 0.991 0.990 0.585 0.990 
F4 0.890 0.924 0.988 0.958 0.532 0.980 
F5 0.849 0.979 0.971 0.911 0.544 0.980 
F6 0.944 0.808 0.997 0.995 0.573 0.957 
From the Table, it is proposed that the formulation follows zero order with regression 
value of 0.944. n value of Peppas equation was found to be 0.573. So the drug release 
follows non-fickian diffusion or anomalous release (0.45<n<1). Thus release was 
dependant both on drug diffusion and polymer relaxation. Based on the correlation 
coefficient obtained for higuchi‟s square root equation (0.997) and Hixson crowell cube 
root equation (0.957), drug release kinetics corresponds best to higuchi‟s model.  
Thus the result shows that formulation follows zero order release kinetics. Drug release 
kinetics of this formulation corresponds best to higuchi‟s model. Drug release 
mechanism as per n value of korsmeyer peppas equation was found to be complex 
mechanism of swelling, diffusion and erosion.  
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STABILITY STUDIES: 
65 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
recommended storage conditions, re-test periods and shelf-lives to be established. 
ICH specifies the length of study and storage conditions: 
Long term testing : 25
0
C ± 2
0
C /60% RH ± 5% RH for 12 months. 
Accelerated testing : 40
0
C ± 2
0
C /75% RH ± 5% RH for 6 months. 
The optimised bilayer tablets were subjected to stability studies and results were 
tabulated in following tables: 
Procedure: 
In the present study, stability studies were carried out at 40
0
C ± 2
0
C for a specific time 
period up to 90 days for optimized formulation F6. 
For stability study, the tablets were placed in an ambered coloured vials and sealed with 
aluminium foil, sample containers were placed in desiccators and evaluated for 
physiochemical parameter, drug content and drug release study. 
Table 19: physiochemical data of stability studies 
              
 
 
 
Table 20: Assay and dissolution profile of stability study 
Intervals 
in months 
Drug % drug content Percentage 
cumulative release 
25
0 
C 40˚C 250 C 40˚C 
1
st
 month Metformin HCl 99.97 99.24 98.73 99.16 
Glimepiride 100.1 99.98 99.71 100.07 
2
nd
 month Metformin HCl 98.86 97.25 98.45 98.56 
Glimepiride 99.29 100.2 100.02 99.61 
3
rd
 month Metformin HCl 99.26 98.59 99.86 98.63 
Glimepiride 98.52 99.65 98.79 97.25 
 
 
Parameters 1
st
 month 2
nd
 month 3
rd
 month 
25
0 
C 40˚C 250 C 40˚C 250 C 40˚C 
Colour 
No characteristic Changes 
Thickness 
Hardness 
Friability 
DISCUSSION 
The study describes the formulation of both immediate and sustained release drug for 
increased therapeutic efficacy and patient convenience. The bilayer tablets were 
prepared by wet granulation method using IPA as a solvent which has been tried many 
times for the good release behaviour by taking various polymers. Unit formula was 
given in Table 8 & 9. Suitable formulation has been optimized. Tablet average weight is 
1050mg, Thickness 6.7mm, Hardness 9-12kg/cm
2
, Friability is 0.4% drug loss. 
The physical compatibility evaluation was performed in visual basis. The study implies 
that the drug, polymer and other excipients were physically compatible with each other 
as there was no change of physical description. The results have been shown in the 
Table 4.The FT-IR spectrum of Glimepiride and Metformin HCl in formulation F6 was 
shown in the Figure 4 to 8 respectively. The spectra revealed the presents of peaks at 
3367 cm
-1
 and 1458 cm
-1 
  respectively (Table 5, 6) indicating that there was no 
interaction between drug and polymer used in the study. 
The tablets of different formulations were subjected preformulation studies such as 
angle of repose, bulk density, tapped density, haussner‟s ratio, compressibility index 
and post compression parameters such as compressibility index, weight variation, 
thickness, hardness, friability and drug content. The results are shown in the Table no 
12 & 15. All the formulation passes the test as per IP, 2007. 
Figure 12 shows comparative percentage drug release of Glimepiride. The percentage in 
vitro drug release from formulations F1 to F6 ranged from 99.0% to 101.55% within 30 
minutes. It‟s due to SSG as superdisintegrant in IR formulations. Figure 11 shows 
comparative percentage drug release of Metformin HCl. The percentage in vitro drug 
release from formulations F1 to F6 is shown in table 16. Complete release of drug 
occurred from the bilayer tablets within 10 hours. 
The result suggested that various variables affecting the dissolution of the tablets. The 
optimization of the tablets was done based on experimental result such as its 
physiochemical parameters, dissolution and content uniformity. The tablets produced 
were stable and reliable. Formulation F6 shows better in-vitro drug release. So it is 
suggested that for highly water soluble drug like Metformin HCl, combination of 
different polymer can be used. The release data further indicated that combination of 
SCMC and HPMC K 100M gives sustained release effect followed by the initially burst 
release effect due to the superdisintigrant SSG in immediate release layer. 
The kinetics parameters of Metformin HCl release are shown in Table 18.  It can be 
best expressed by Higuchi‟s and kosmeyer‟s peppas model (Fig: 15 & 16) as the plots 
showed high linearity and confirms diffusion mechanism (non fickian transport).  
The stability study of the formulation F6 was done at 40
0
c/75%RH for three months and 
it shows better stability of the product (Table 19 & 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
The present work was aimed towards developing a bilayer tablets containing 
Glimepiride as immediate release and Metformin HCl as sustained release. The tablets 
were prepared using techniques of wet granulation and compression. The optimization 
of the tablets was done based on experimental result such as its physiochemical 
parameters, dissolution and content uniformity. The tablets produced were stable and 
reliable. The result suggested that various variables affecting the dissolution of the 
tablets. Formulation F6 shows better dissolution. So it is suggested that for highly water 
soluble drug like Metformin HCl, it is desirable to use combination of different polymer 
for sustained release layer and incorporation of superdisintegrant like SSG in immediate 
release layer. The release data further indicated that combination of SCMC and HPMC 
K 100M can give the sustained release effect followed by the initially burst release 
effect due to the superdisintegrant SSG in immediate release layer. HPMC K100M 
polymer controlled the release of Metformin HCl up to 10 hrs intended for once daily 
administration. The release data of in vitro study indicates that formulation follows zero 
order, Higuchi equation and diffusion takes place via non-fickian transport. Formulation 
F6 found to be stable at accelerated stability as per the ICH guidelines for a period of 3 
months. 
 Finally it concluded that Glimepiride as immediate release and Metformin HCl 
as sustained release indicate promising potential of both drugs in the form of bilayer 
tablets an alternative to the conventional dosage form.  
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